SCHEMBL732742

SCHEMBL732742

O=C(Oc1cccs1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP12 P39900 1/20 0.53
PLA2G7 Q13093 1/20 0.53
HPGD P15428 4/20 0.50
ALDH1A1 P00352 3/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
KMT2A Q03164 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
RAB9A P51151 3/20 0.49
PKM P14618 3/20 0.49
NPC1 O15118 2/20 0.49
PARP10 Q53GL7 1/20 0.49
HPGDS O60760 1/20 0.48
LMNA P02545 3/20 0.48
F2 P00734 1/20 0.48
MAPT P10636 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27346459 0.92 MMP1 (0.56) MMP1MMP2MMP9MMP12PLA2G7
SCHEMBL27816663 0.90 SMN1; SMN2 (0.53) MMP1MMP2MMP9MMP12PLA2G7
SCHEMBL8207067 0.84 MAPT (0.56) MMP1MMP2MMP9MMP12HPGD
SCHEMBL27553236 0.84 MMP1 (0.49) MMP1MMP2MMP9MMP12PLA2G7
SCHEMBL30481362 0.84 MMP1 (0.49) MMP1MMP2MMP9MMP12KMT2A
SCHEMBL30291063 0.82 MMP1 (0.54) MMP1MMP2MMP9MMP12PLA2G7
SCHEMBL29276385 0.82 MMP1 (0.57) MMP1MMP2MMP9MMP12PLA2G7
SCHEMBL28660859 0.80 MMP1 (0.49) MMP1MMP2MMP9MMP12HPGD
SCHEMBL1036006 0.79
SCHEMBL28667021 0.79 SRPK1 (0.51) MMP1MMP2MMP9MMP12HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113725370-B TiO in solar cell2Passivation method for electron transport layer 西安石油大学 2024-07-16 CN claimed
US-20220409602-A1 DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF DYSKINESIA TEXAS BIOMEDICAL RESEARCH INSTITUTE (US) 2022-12-29 US claimed
CN-105669506-A Synthetic method of 2-thiophenylbenzoic acid 温州大学 2016-06-15 CN claimed
CN-101525333-B Synthesis method of metixene hydrochloride UNIV EAST CHINA NORMAL 2011-04-27 CN claimed
CN-101525333-A Synthesis method of metixene hydrochloride UNIV EAST CHINA NORMAL 2009-09-09 CN claimed
US-20050130207-A1 Small organometallic probes HAINFELD JAMES F (US) 2005-06-16 US claimed
US-6369206-B1 OF THE FORMULA (M)N(SR)M WHERE M IS GOLD, SILVER, PLATINUM, PALLADIUM, OR THALLIUM, AND (SR)M IS ORGANOTHIOL MOIETIES; BIOCONJUGATES NANOPROBES, INC 2002-04-09 US claimed
CN-1036590-C Process for preparing mercaptoacetylamide derivatives MERRELL DOW PHARMA (US) 1997-12-03 CN claimed
CN-1061971-A Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and angiotensin converting enzyme MERRELL DOW PHARMA (US) 1992-06-17 CN claimed
JP-4282382-A None JP disclosed
CN-114839180-B Preparation method of spray type bi-component composite Raman substrate 电子科技大学 2023-08-01 CN disclosed
CN-115947690-A Preparation method of indazole molecular building block and application of building block in drug synthesis 安徽医科大学 2023-04-11 CN disclosed
US-20220409602-A1 DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF DYSKINESIA TEXAS BIOMEDICAL RESEARCH INSTITUTE (US) 2022-12-29 US disclosed
CN-105669506-A Synthetic method of 2-thiophenylbenzoic acid 温州大学 2016-06-15 CN disclosed
CN-1054590-A The benzoic acid herbicides that 6-aryl-2-replaces FMC CORP (US) 1991-09-18 CN disclosed
CN-1034721-A New tricyclic lactam that contains sulfydryl and the method for on pharmacology, using thereof MERRELL DOW PHARMA (US) 1989-08-16 CN disclosed
EP-0105224-B1 ANDROSTENES AND PROCESS FOR THEIR PREPARATION E.R. Squibb & Sons, Inc. (US) 1987-01-21 EP disclosed
US-4446071-A Intermediates useful in the preparation of 17,17-bis(substituted thio) androstenes E. R. SQUIBB & SONS, INC. (US) 1984-05-01 US disclosed
EP-0105224-A2 Androstenes and process for their preparation E.R. Squibb & Sons, Inc. (US) 1984-04-11 EP disclosed
US-4435326-A Intermediates useful in the preparation of 17,17-bis(substituted thio)androstenes E. R. SQUIBB & SONS, INC. (US) 1984-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409602-A1 DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF DYSKINESIA DRD3, PARK7, DRD2 MMP1 4448/4885MMP2 3646/4885MMP9 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.